ArticleBritish journal of cancer1994
The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
Article in British journal of cancer, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.Frontiers in immunology · 2024Pooled it
- Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease.International journal of gastrointestinal cancer · 2002Trial
- Autoantibodies as biomarkers for breast cancer diagnosis and prognosis.Frontiers in immunology · 2022Review
- Autoantibodies in Early Detection of Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- An electrochemiluminescence biosensor for p53 antibody based on Zn-MOF/GO nanocomposite and AgMikrochimica acta · 2020Article
- Mutant p53 as an Antigen in Cancer Immunotherapy.International journal of molecular sciences · 2020Review
- Autoantibodies as Potential Biomarkers in Breast Cancer.Biosensors · 2018Review
- Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer.Oncotarget · 2017Article
- The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.Targeted oncology · 2017Review
- Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.Medical oncology (Northwood, London, England) · 2010Article
- Autoantibodies to tumor-associated antigens in breast carcinoma.Journal of oncology · 2010Article
- Role of traditional and new biomarkers in breast carcinogenesis.Ecancermedicalscience · 2009Article
- Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.World journal of gastroenterology · 2008Article
- Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.British journal of cancer · 2000Article
- P53 autoantibodies in 1006 patients followed up for breast cancer.Breast cancer research : BCR · 2000Article
- Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.British journal of cancer · 1999Article
- p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.British journal of cancer · 1999Article
- Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.British journal of cancer · 1999Article
- Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.British journal of cancer · 1998Article
- p53 and follow-up of colorectal adenocarcinomas.Digestive diseases and sciences · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sera from 182 newly diagnosed breast cancer patients were assayed for antibodies to p53 using an enzyme-linked immunosorbent assay (ELISA) method, and antibodies were detected in 48 (26%) compared with 1 out of 76 (1.3%) normal control volunteers (P = 0.0001). In breast cancer patients, autoantibodies were found in all stages of disease progression: carcinoma in situ, primary invasive breast cancer and in metastatic disease. In the subset of patients in whom sequential sera were assessed over a 6 month period, changes in the p53 antibody titres were observed. The presence of antibodies to p53 correlated positively with high histological grade (P = 0.0012) and a history of second primary cancer (six positive out of eight cases). The incidence of autoantibodies was lower in those patients with a first-degree relative with breast cancer (P = 0.046). Out of 68 patients, there was a significant correlation between positive p53 autoantibody status and the detection of p53 protein in the tissue sections by immunocytochemistry (P = 0.002). In the seronegative patients, positive p53 tumour staining was strongly associated with a family history of breast cancer (P = 0.009). The p53 protein overexpressed in heritable breast cancers may therefore be less immunogenic. The presence of p53 autoantibodies provides important additional information to immunochemistry and may identify patients with aggressive histological types of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.